Company Profiles

driven by the PitchBook Platform

AmVac

AmVac
2005 FOUNDED
OOB STATUS
11-50 EMPLOYEES
Liquidation LATEST DEAL TYPE
$4M TOTAL AMOUNT RAISED
Description

Developer of vaccines designed to offer breakthrough results from basic research efficiently into the industrial development. The company's vaccines are innovative and safe that enhance human health and improve scientific understanding of immunological conditions and focuses on the fast growing vaccine market in the fields of gynecology, urology and lung diseases, enabling patients to have stimulated immune system against invading pathogens.

Website:
Ownership Status
Out of Business
Financing Status
Formerly VC-Backed
Primary Industry
Drug Discovery
Primary Office
Baarerstrasse 22
6300 Zug
Switzerland

+41 (0)41 725 3230
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AmVac’s full profile, request a free trial.

AmVac Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Bankruptcy: Liquidation 01-Jan-2016 $4M Completed Bankruptcy: Liquidation
3. Grant 20-Jun-2013 000.00 000 Completed Generating Revenue
2. Early Stage VC (Series A) 11-Feb-2010 $2.8M $4M Completed Startup
1. Early Stage VC $1.2M $1.2M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

AmVac Executive Team (2)

Name Title Board
Seat
Contact
Info
Ali Pashazadeh Chief Executive Officer
Marian Wiegand MD Head, Research & Development

You’re viewing 2 of 2 executives.

AmVac Board Members (2)

Name Representing Role Since Contact
Info
Keith Luxon Self President, Supervisory Board 000 0000
Viktor Sauter Self Board Member 000 0000

You’re viewing 2 of 2 board members.